Risk factors
Insulet (PODD) risk factors
Item 1A of every Insulet Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors36 risks5 new9 dropped20 reworded
International sales reached 28% of 2025 revenue as Omnipod 5 launches expand, with greater exposure to foreign operations and tariffs.
Filed Feb 18, 2026 - FY2024 10-K risk factors40 risks
Nearly all revenue depends on the Omnipod platform and its pharmacy channel distribution. Manufacturing relies heavily on a new Malaysian facility, a US site, and a Chinese contractor. Substantially all Drug Delivery revenue relies on Amgen's Neulasta Onpro kit agreement expiring in December 2028.
Filed Feb 21, 2025